Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
19.12
-0.38 (-1.95%)
At close: Oct 10, 2025, 4:00 PM EDT
19.51
+0.39 (2.04%)
After-hours: Oct 10, 2025, 6:22 PM EDT
Seres Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
103
Market Cap
167.39M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
| Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
| Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
| Dec 31, 2018 | 28.27M | -3.83M | -11.94% |
| Dec 31, 2017 | 32.10M | 10.33M | 47.48% |
| Dec 31, 2016 | 21.77M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
MCRB News
- 19 days ago - Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway - GlobeNewsWire
- 20 days ago - More companies adopt co-CEO structure - Reuters
- 6 weeks ago - Seres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 2 months ago - Seres Therapeutics, Inc. (MCRB) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough - Seeking Alpha
- 2 months ago - Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025 - GlobeNewsWire
- 2 months ago - Seres Therapeutics Announces Leadership Transition - GlobeNewsWire